MET: a Critical Player in Tumorigenesis and Therapeutic Target

Overview

Journal Cold Spring Harb Perspect Biol

Specialties Biology
Molecular Biology

Date 2013 Jul 3

PMID 23818496

Citations 70

Authors

Carrie R Graveel

David Tolbert

George F Vande Woude

Affiliations

Soon will be listed here.

Abstract

Since its discovery more than 25 years ago, numerous studies have established that the MET receptor is unique among tyrosine kinases. Signaling through MET is necessary for normal development and for the progression of a wide range of human cancers. MET activation has been shown to drive numerous signaling pathways; however, it is not clear how MET signaling mediates diverse cellular responses such as motility, invasion, growth, and angiogenesis. Great strides have been made in understanding the pleotropic aspects of MET signaling using three-dimensional molecular structures, cell culture systems, human tumors, and animal models. These combined approaches have driven the development of MET-targeted therapeutics that have shown promising results in the clinic. Here we examine the unique features of MET and hepatocyte growth factor/scatter factor (HGF/SF) structure and signaling, mutational activation, genetic mouse models of MET and HGF/SF, and MET-targeted therapeutics.

Citing Articles

Digestive cancers: mechanisms, therapeutics and management.

Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M Signal Transduct Target Ther. 2025; 10(1):24.

PMID: 39809756 PMC: 11733248. DOI: 10.1038/s41392-024-02097-4.

hnRNPU-mediated pathogenic alternative splicing drives gastric cancer progression.

Jin G, Song Y, Fang S, Yan M, Yang Z, Shao Y J Exp Clin Cancer Res. 2025; 44(1):8.

PMID: 39773744 PMC: 11705778. DOI: 10.1186/s13046-024-03264-9.

Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions.

Wang K, Hsu R Antibodies (Basel). 2024; 13(4).

PMID: 39449330 PMC: 11503282. DOI: 10.3390/antib13040088.

Establishment of a tumor-associated fibroblast associated gene score based on scRNA-seq to predict prognosis in patients with triple-negative breast cancer.

Yu H, Peng Z, Li X, Zhang Y PLoS One. 2024; 19(10):e0311801.

PMID: 39418248 PMC: 11486389. DOI: 10.1371/journal.pone.0311801.

Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation.

Huang S, Long Y, Gao Y, Lin W, Wang L, Jiang J Exp Hematol Oncol. 2024; 13(1):97.

PMID: 39354638 PMC: 11443824. DOI: 10.1186/s40164-024-00565-9.

References

Muller M, Morotti A, Ponzetto C . Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol. 2002; 22(4):1060-72. PMC: 134627. DOI: 10.1128/MCB.22.4.1060-1072.2002. View

Cao B, Su Y, Oskarsson M, Zhao P, Kort E, Fisher R . Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A. 2001; 98(13):7443-8. PMC: 34688. DOI: 10.1073/pnas.131200498. View

Gu H, Maeda H, Moon J, Lord J, Yoakim M, Nelson B . New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol Cell Biol. 2000; 20(19):7109-20. PMC: 86258. DOI: 10.1128/MCB.20.19.7109-7120.2000. View

Lee J, Han S, Cho H, Jennings B, Gerrard B, Dean M . A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 2000; 19(43):4947-53. DOI: 10.1038/sj.onc.1203874. View

Lamorte L, Rodrigues S, Naujokas M, Park M . Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the met morphogenic program. J Biol Chem. 2002; 277(40):37904-11. DOI: 10.1074/jbc.M201743200. View

Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P . Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997; 16(1):68-73. DOI: 10.1038/ng0597-68. View

Huh C, Factor V, Sanchez A, Uchida K, Conner E, Thorgeirsson S . Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A. 2004; 101(13):4477-82. PMC: 384772. DOI: 10.1073/pnas.0306068101. View

Youles M, Holmes O, Petoukhov M, Nessen M, Stivala S, Svergun D . Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist. J Mol Biol. 2008; 377(3):616-22. DOI: 10.1016/j.jmb.2008.01.034. View

Park W, Dong S, Kim S, Na E, Shin M, Pi J . Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999; 59(2):307-10. View

10.

Kong-Beltran M, Stamos J, Wickramasinghe D . The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004; 6(1):75-84. DOI: 10.1016/j.ccr.2004.06.013. View

11.

Bardella C, Costa B, Maggiora P, Patane S, Olivero M, Ranzani G . Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res. 2004; 64(15):5154-61. DOI: 10.1158/0008-5472.CAN-04-0600. View

12.

Grant D, Kleinman H, Goldberg I, Bhargava M, Nickoloff B, Kinsella J . Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A. 1993; 90(5):1937-41. PMC: 45995. DOI: 10.1073/pnas.90.5.1937. View

13.

Corso S, Comoglio P, Giordano S . Cancer therapy: can the challenge be MET?. Trends Mol Med. 2005; 11(6):284-92. DOI: 10.1016/j.molmed.2005.04.005. View

14.

Stahl S, Wingfield P, Kaufman J, Pannell L, Cioce V, Sakata H . Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. Biochem J. 1997; 326 ( Pt 3):763-72. PMC: 1218731. DOI: 10.1042/bj3260763. View

15.

Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H . Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst. 1999; 91(18):1548-56. DOI: 10.1093/jnci/91.18.1548. View

16.

Donate L, Gherardi E, Srinivasan N, Sowdhamini R, Aparicio S, Blundell T . Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci. 1994; 3(12):2378-94. PMC: 2142779. DOI: 10.1002/pro.5560031222. View

17.

Saucier C, Khoury H, Lai K, Peschard P, Dankort D, Naujokas M . The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sci U S A. 2004; 101(8):2345-50. PMC: 356953. DOI: 10.1073/pnas.0308065101. View

18.

Park M, Dean M, Cooper C, Schmidt M, OBrien S, Blair D . Mechanism of met oncogene activation. Cell. 1986; 45(6):895-904. DOI: 10.1016/0092-8674(86)90564-7. View

19.

Camp E, Liu W, Fan F, Yang A, Somcio R, Ellis L . RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol. 2005; 12(4):273-81. DOI: 10.1245/ASO.2005.08.013. View

20.

Holmes O, Pillozzi S, Deakin J, Carafoli F, Kemp L, Butler P . Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J Mol Biol. 2007; 367(2):395-408. DOI: 10.1016/j.jmb.2006.12.061. View